trending Market Intelligence /marketintelligence/en/news-insights/trending/EG6oOLZlb_6EXg__1xeYug2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

HVIVO director resigns

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

HVIVO director resigns

HVIVO PLC said Graham Yeatman stopped being a director of the company, effective Dec. 31, 2018.

As previously announced in September 2018, Yeatman also stepped down as hVIVO's chief financial and business officer.

He joined the company's board as finance director in 2011 and was promoted to the chief financial and business officer post in 2015.

The company has named Shelley Fraser to replace Yeatman as finance director.

London-based hVIVO is developing a human-based clinical trial platform for drug and vaccine development in respiratory and infectious diseases.